Preprint
Review

This version is not peer-reviewed.

The Evolution of Canaloplasty: Two Decades of Restoring and Reinforcing the Conventional Outflow Pathway

Submitted:

12 November 2026

Posted:

16 November 2026

You are already at the latest version

Abstract
Surgery of Schlemm’s canal has evolved over two decades from bleb-dependent, ab-externo viscocanalostomy into a family of tissue-sparing, ab-interno, and scaffold-reinforced procedures. We trace five generations of canal surgery and evaluate whether durable structural reinforcement of the restored canal, with preservation of the trabecular meshwork, determines long-term outcome. Imaging and histology show that the glaucomatous canal is narrowed and partially collapsed, with canal area inversely related to intraocular pressure. Viscoelastic injected into the canal is cleared within 24 hours, whereas a tensioning suture sustains canal expansion beyond 20 months and outperforms viscocanalostomy, particularly at stringent pressure targets. Ab-interno canaloplasty sustains pressure and medication reduction for 3 to 6 years but leaves no structural element in the canal. A nitinol intracanalicular scaffold has 5-year randomized evidence of benefit but provokes persistent angle reactivity, with cumulative peripheral anterior synechiae of 14.6% versus 3.7% after cataract surgery alone. Acellular scleral allograft is safe and non-migrating as a uveoscleral cleft scaffold but has not been studied inside Schlemm’s canal. Biologic intracanalicular reinforcement is a coherent but untested next step that requires randomized, morphometric evaluation.
Keywords: 
;  ;  ;  ;  ;  ;  ;  

1. Introduction

For two decades, surgery of Schlemm’s canal has pursued one organizing principle: restore the anatomy and patency of the conventional outflow pathway rather than destroy or bypass it [15,36]. This review traces five surgical generations (viscocanalostomy, suture-tensioned canaloplasty, ab-interno catheter canaloplasty, synthetic intracanalicular scaffolding and, most recently, homologous scleral allograft reinforcement) and evaluates whether the evidence supports that durable structural reinforcement of the restored canal, with the trabecular meshwork preserved, governs long-term efficacy.

1.1. The Conventional Outflow Pathway as a Surgical Target

Aqueous humor leaves the eye predominantly through the trabecular meshwork, Schlemm’s canal, collector channels, deep scleral plexus and aqueous and episcleral veins; a smaller fraction exits by the uveoscleral route [15,36]. Schlemm’s canal is a circumferential vessel with blood and lymphatic features embedded in the deep sclera at the corneoscleral junction. Its outer wall is supported by scleral connective tissue, and the trabecular meshwork inserts posteriorly on the scleral spur [15]. Outflow around this ring is segmental, with discrete high-flow and low-flow regions, so sector-limited procedures may or may not engage productive drainage territory [15].
The dominant site of resistance in the normal eye lies in the juxtacanalicular connective tissue and the inner wall endothelium of Schlemm’s canal [6,59,64]. Classic perfusion work localized roughly three-quarters of resistance proximal to the canal lumen, with the remainder distal [24]. This distal fraction, together with an episcleral venous pressure of approximately 8 to 11 mmHg in seated individuals [57], sets a floor that no canal procedure can breach.

1.2. The Glaucomatous Canal: Stiffening, Narrowing, and Collapse

In primary open-angle glaucoma, juxtacanalicular cells acquire a contractile, myofibroblast-like phenotype with an expanded actin cytoskeleton and fibrillar extracellular matrix under transforming growth factor-β and connective tissue growth factor signaling, stiffening the inner wall region [6,64]. Schlemm’s canal endothelial cells from glaucomatous eyes are themselves stiffer and form fewer pores [51], and loss of trabecular cellularity further degrades homeostatic regulation [36].
These changes have a measurable morphological correlate. In perfusion-fixed eyes, glaucomatous canals had smaller cross-sectional area, perimeter and inner wall length than normal canals, and reduced inner wall length accounted for a substantial share of the facility deficit [3]. Spectral-domain optical coherence tomography (OCT) showed mean canal area of 11,332 ± 2,015 μm2 in primary open-angle glaucoma versus 13,991 ± 1,357 μm2 in controls (p < 0.001), inversely correlated with intraocular pressure (IOP) [31]. Swept-source OCT with three-dimensional reconstruction confirmed reduced en-face area, visibility, and diameter in glaucomatous eyes [32]. Ultrasound biomicroscopy detected the canal in only 53.1% of glaucomatous sections versus 80.3% of normal sections [69]. Trabeculectomy specimens show frank lumen collapse in elderly-onset primary open-angle glaucoma and endothelial dropout with shortened canal length in juvenile disease [30]. Experimentally, loss of angiopoietin–Tie2 signaling degrades canal integrity and reproduces the glaucoma phenotype in adult mice, with comparable integrity loss during natural aging [39]. Ocular hypertension in primary open-angle glaucoma, therefore, is often partially attributable to structural narrowing and stiffening of the conduit. Surgery that reopens and holds the conduit addresses the lesion at its anatomical site.

1.3. Preservation Versus Ablation

Two strategies have coexisted. The ablative strategy (Trabectome (MicroSurgical Technology), excisional goniotomy, gonioscopy-assisted transluminal trabeculotomy, microhook trabeculotomy) removes or incises the trabecular meshwork to expose collector ostia directly to the anterior chamber [68]. The restorative strategy (viscocanalostomy, canaloplasty, canal scaffolding) reopens the canal and re-tensions the trabecular meshwork while leaving it intact.
Ablative procedures lower IOP and medication burden across open-angle, steroid-induced, uveitic and exfoliative glaucoma [10,16,46] but carry structural costs. First, the trabecular meshwork is a mechanoresponsive tissue whose cellularity, matrix turnover, and contractile tone participate in IOP homeostasis [37]; excision forfeits that regulatory capacity and forecloses future trabecular-directed therapy [6,36,59,64]. Second, trabeculectomy specimens from eyes previously treated with microhook trabeculotomy showed the lumen of Schlemm’s canal partially sealed by scleral tissue, with endothelial dropout and conversion of segments into ghost vessels [67]. Third, wound healing and fibrotic re-closure at the treated angle drive late failure across trabecular procedures [10]. Fourth, hemorrhage is common: hyphema occurred in nearly half of goniotomy and gonioscopy-assisted transluminal trabeculotomy cases in a pooled exfoliation analysis, with IOP spikes in 17% [46], and gonioscopy-assisted transluminal trabeculotomy achieves lower IOP than viscodilation at the cost of more frequent hyphema [66].
Canal-preserving surgery accepts a more modest ceiling of IOP reduction in exchange for anatomical reversibility, no bleb, no antifibrotic exposure, very low hypotony risk and retention of every downstream surgical option. The low hypotony rate permits use in advanced glaucoma, where sudden pressure collapse is a genuine hazard [11,62].

2. Five Generations of Canal-based Procedures

2.1. Generation One: Viscocanalostomy

Stegmann’s viscocanalostomy established that Schlemm’s canal could be re-expanded to restore physiological drainage without a filtering bleb, combining deep sclerectomy with viscoelastic expansion of the canal ostia [60]. Randomized comparisons and a Cochrane review show greater IOP reduction with trabeculectomy and fewer complications with non-penetrating surgery [19,22]. Outcomes were durable but heterogeneous: one series achieved unmedicated IOP below 21 mmHg in only 36% at 1 year, with subconjunctival drainage in most eyes despite watertight flap closure [18]; others reported 88% overall success at 3 years [61] and 90% below 21 mmHg at 5 years, although 37% required Nd:YAG goniopuncture [56]. The largest experience, 726 eyes followed for a mean of 86 months, reported mean IOP of 15.4 mmHg at 5 years and 15.5 mmHg at 10 years with no blebitis or endophthalmitis [26], the defining safety signature of bleb-independent canal surgery.
Viscoelastic alone proved insufficient. In primate and human eyes, viscoelastic injection dilates Schlemm’s canal and collector channels acutely but frequently disrupts the canal walls, inner wall endothelium and septa [29,58]. Endoscopy with indocyanine green-stained viscoelastic showed the material absent from the canal on the first postoperative day [63]. Viscodilation is a hydraulic event, not a structural one; the dilated canal requires something to hold it open, failing which the unsupported lumen collapses back toward its narrowed, preoperative state [29,63].

2.2. Generation Two: Suture-Tensioned Canaloplasty

Canaloplasty, introduced in the mid-2000s, added a 360° microcatheter viscodilation and a 10-0 polypropylene suture tied under tension within the canal, applying inward traction on the trabecular meshwork44. This was the first permanent, non-viscoelastic structural element placed in Schlemm’s canal.
In the pivotal multicenter study, 157 eyes reached a mean IOP of 15.2 ± 3.5 mmHg on 0.8 ± 0.9 medications at 3 years from 23.8 ± 5.0 mmHg on 1.8 ± 0.9; combined phacocanaloplasty reached 13.6 ± 3.6 mmHg on 0.3 ± 0.5 [9,45]. Pressure reduction was maintained at 10 to 11 years [20]. In a 3-year series of 160 eyes, IOP fell by 36.7% and medications from 2.69 to 0.32, but cannulation was incomplete in 20%, the principal technical limitation of the ab-externo approach [42]. In African patients with severe primary open-angle glaucoma and a mean baseline IOP of 45.0 mmHg, canaloplasty achieved 13.3 mmHg at 36 months with 77.5% complete success, and baseline IOP did not predict failure [27].
The cleanest test of the tensioning suture is an intra-individual study comparing canaloplasty in one eye with viscocanalostomy in the fellow eye, eliminating inter-patient confounding: canaloplasty produced lower IOP (14.5 ± 2.6 vs 16.1 ± 3.9 mmHg; p = 0.02) [41]. A retrospective cohort of 600 eyes across nine European units, comparing canaloplasty, deep sclerectomy and viscocanalostomy, found 2-year qualified success at the stringent criterion of IOP ≤15 mmHg with ≥25% reduction in 76.6% of canaloplasty eyes versus 39.0% of viscocanalostomy eyes [47]. The separation widened as the target became more demanding, the pattern predicted if an unsupported canal partially re-collapses.
Imaging confirms durable lumen expansion. OCT and ultrasound biomicroscopy after suture canaloplasty showed early canal height and width increases of 369% and 152%, with IOP inversely correlated to canal height [21]. At 20 ± 4.9 months the same cohort retained increases of 351% and 144%, the suture was visible within the canal in 75% of eyes, and IOP had fallen from 23.4 to 12.6 mmHg on 0.4 medications [43]. These dimensions are supraphysiologic. They reflect sustained mechanical distension, not restoration of normal architecture or tissue regeneration.

2.3. Generation Three: Ab-interno Canaloplasty

The ab-externo approach required conjunctival dissection, a scleral flap and deep sclerectomy, imposed a steep learning curve and failed to cannulate the full canal in a fifth of eyes [8,42]. Ab-interno canaloplasty preserved the mechanism without that morbidity: through a clear corneal incision, a microcatheter (iTrack, Nova Eye Medical) or cannula system (OMNI, Sight Sciences; STREAMLINE, New World Medical) delivers pressurized viscoelastic within Schlemm’s canal, which is thought to separate compressed trabecular lamellae and withdraw herniated inner wall tissue from collector ostia [68].
A meta-analysis of standalone OMNI canaloplasty with trabeculotomy (five studies, 290 eyes) reported mean IOP reductions of 7.4 mmHg at 1 year and 8.8 mmHg at 2 years, with 46.2% medication-free at 1 year [70]. In the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight), 230 standalone eyes, 81% with moderate or severe primary open-angle glaucoma, fell from 22.1 mmHg to 15.1 to 16.7 mmHg through 36 months [52]. A prospective international iTrack registry of 344 eyes followed a mean of 20.5 months reported IOP falling from 17.2 to 14.1 mmHg and medications from 2.1 to 1.3 in combined cases, 43% medication-free versus 7% preoperatively, 4.9% requiring further glaucoma surgery and no sight-threatening canaloplasty complications [38]. Among 206 eyes treated with VISCO360 (Sight Sciences) or OMNI, 73% met the primary endpoint and IOP reduction persisted to 42 months [49]; a smaller iTrack series reported IOP falling from 19.9 to 14.6 mmHg at 6 years [40]. The first randomized trial involving canaloplasty found comparable IOP and medication reduction for STREAMLINE canaloplasty and iStent inject (Glaukos) when each was combined with phacoemulsification [23].
Ab-interno canaloplasty thus delivers canal preservation in a minimally invasive package. Its acknowledged limitation is the one that constrained viscocanalostomy: the dilating agent is transient and no structural element remains [29,63].

2.4. Generation Four: Synthetic Intracanalicular Scaffolds

If viscoelastic is gone within 24 hours and a tensioning suture sustains expansion beyond 20 months, the next step is a purpose-built scaffold.
  • Stegmann Canal Expander
In human autopsy eyes, the Stegmann Canal Expander (Ophthalmos GmbH) held the canal open along its full 9-mm length with an unchanged 240-μm lumen, no wall disruption and persistent trabecular distension, whereas viscodilation alone disrupted the walls [29]. Clinically, 42 eyes with primary open-angle glaucoma receiving two expanders over 180° reached 13.3 ± 2.5 mmHg from 26.8 mmHg at 24 months, with 80% complete success (IOP ≤16 mmHg and ≥30% reduction) and medications falling from 2.8 to 0.2 [25,28].
2.
Hydrus Microstent
The Hydrus Microstent (Alcon) is an 8-mm nitinol scaffold that bypasses the trabecular meshwork at its inlet and dilates roughly three clock hours of Schlemm’s canal. In the HORIZON trial (556 eyes randomized 2:1 to Hydrus with cataract surgery or cataract surgery alone), the Hydrus arm at 5 years had a higher proportion with unmedicated IOP ≤18 mmHg (49.5% vs 33.8%; p = 0.003), a greater likelihood of ≥20% unmedicated reduction (54.2% vs 32.8%; p < 0.001), 66% versus 46% medication-free, and a lower cumulative rate of incisional glaucoma surgery (2.4% vs 6.2%; p = 0.027), with no difference in endothelial cell loss [1,54]. A post hoc analysis found slower visual field progression with the scaffold (−0.26 vs −0.49 dB/year; p = 0.0138), only 17% of which was explained by the IOP difference [48]. In a Cochrane review, Hydrus lowered IOP by approximately 3 mmHg more than two first-generation iStents [50], and a 5-year comparative cohort showed equivalent treated IOP but greater medication sparing with Hydrus (medication-free success 63.6% vs 20.0%) [35]. A propensity-matched registry of 431 eyes, however, found no difference in 48-month success between Hydrus and iStent inject, each combined with phacoemulsification (41.2% vs 43.0%) [65].
3.
Tissue Reactivity of Synthetic Scaffolds
An implant in the angle is not inert. The most frequent adverse finding in HORIZON was peripheral anterior synechiae at or near the device inlet. At 2 years, peripheral anterior synechiae or iris tissue at the inlet was recorded in 18.7% of Hydrus eyes, obstructive in 3.8% and non-obstructive in 14.9% [55]. Through 5 years, cumulative peripheral anterior synechiae reached 14.6% versus 3.7% after cataract surgery alone (p = 0.0001), roughly a four-fold excess, with partial or complete device obstruction in 8.4%, malposition in 1.4% and persistent anterior uveitis in 0.5% [1]. In the COMPARE trial, peripheral anterior synechiae were the leading cause of Hydrus inlet obstruction, whereas iris and tissue adhesions predominated with iStents [2]. Most HORIZON synechiae were focal, under one clock hour (30 of 42 eyes, 71.4%), without measurable effect on IOP or acuity [1], so synechiae are best read as a marker of persistent angle reactivity rather than a proven cause of failure.
Histology points the same way. Trabecular meshwork harvested next to explanted trabecular bypass stents showed loss of trabecular cells, collapse of collagen beams and a membrane overlying the implant [13], and malposition can provoke uveitis-glaucoma-hyphema syndrome [14]. These findings fit the canonical foreign body response to synthetic materials: protein adsorption, macrophage fusion into foreign body giant cells and fibrous encapsulation that persists for the life of the implant [4]. In the supraciliary space, fibrotic material occupied the lumen of six of nine CyPass microstents (Alcon) explanted for failure [33]. Acellular extracellular matrix scaffolds follow a different course: in experimental models they are degraded and remodeled under a predominantly constructive, M2 macrophage response rather than encapsulated [5,7]. Whether this biomaterial principle yields fewer synechiae and less fibrosis in the human angle has not been tested.
Malposition, chronic contact with adjacent tissue, and a permanent non-resorbable metallic implant in an eye that may live for decades are all valid limitations of canal stents [1,66]. Contemporary reviews conclude that canaloplasty may offer comparable efficacy without implant-related concerns [66].

2.5. Generation Five: Biologic Scleral Allograft Reinforcement

The newest chapter of canal reinforcement substitutes homologous human scleral tissue for synthetic hardware. Three arguments support it. First, sclera is the native structural substrate of the outflow region: Schlemm’s canal lies within deep sclera and the trabecular meshwork inserts on the scleral spur, so scleral reinforcement is a like-for-like substitution rather than a new material class [15]. Second, acellular scleral allograft has a long ophthalmic safety record in drainage device coverage, scleral perforation and scleromalacia repair, buckle surgery and posterior reinforcement, and favorable biomechanical properties for ab-interno use [17]. Third, no synthetic or metallic element remains. A homologous acellular collagen matrix belongs to the material class that the host integrates and remodels rather than walls off [5,7], so the expected benefit over a synthetic scaffold is less foreign body reaction, less fibrotic encapsulation and, plausibly, less synechial reaction at the outflow interface.
The published clinical experience is in the uveoscleral, not the conventional, pathway: ab-interno cyclodialysis with allograft reinforcement of the cleft (AlloFlo, Iantrek). In 117 eyes combined with cataract surgery, medicated IOP fell 27.1% at 12 months (39.7% in eyes with baseline IOP >21 mmHg), 81.9% reached IOP ≤18 mmHg without additional medication and 3.2% required secondary surgery [34]. In a 2-year single-center series of 31 eyes, 74% achieved ≥20% reduction on the same or fewer medications and mean IOP fell from 21.9 to 12.6 mmHg on 0.55 medications, without serious ocular adverse events [12]. In a prospective multicenter standalone study of 41 eyes, many previously treated with trabecular procedures or laser, IOP fell 31% to 14.7 ± 6.9 mmHg and medications 32% at 12 months, with 71% achieving ≥20% reduction; there was no persistent inflammation, clinically evident rejection, clinically significant hyphema or scaffold migration, and transient IOP elevations of ≥10 mmHg occurred in 17% [53]. Angle status after allograft reinforcement, including peripheral anterior synechiae, has not yet been reported with the gonioscopic rigor of HORIZON, so lower reactivity than synthetic scaffolds is an expectation grounded in biomaterial science, not a demonstrated clinical result.
These data establish that an acellular scleral allograft functions as a safe, non-migrating, conjunctiva-sparing scaffold for maintaining a surgically created outflow space when implanted in the suprachoroidal space. Based on the history of canalicular surgery, it appears that there is a need for intracanalicular reinforcement to ensure a lasting IOP-lowering effect. Intracanalicular allograft reinforcement is a biologically coherent hypothesis, supported by the allograft’s scaffold behavior and by evidence that reinforced canal dilation outperforms viscodilation alone[29,41,47], but it has no direct clinical, comparative, or morphometric support.

3. Synthesis

Table 1 summarizes the trajectory. Five trends emerge: from bleb-dependent to bleb-independent surgery, removing blebitis, endophthalmitis and antifibrotic exposure [26,62]; from ab-externo to ab-interno access, sparing conjunctiva [38,49]; from transient to permanent dilation [29,43,63]; from synthetic toward biologic scaffolds, driven by the angle reactivity that permanent implants provoke [1,4,5,7,17,53,66]; and throughout, from destruction to preservation of a mechanoresponsive trabecular meshwork whose excision is irreversible and can be followed by scleral sealing of the canal [67]. The unifying concept is that conventional outflow surgery should restore the narrowed lumen, re-tension rather than remove the trabecular meshwork, and hold the restored geometry with a durable, biologically appropriate scaffold.

4. Limitations and Research Priorities

Four gaps constrain the argument. First, no longitudinal imaging study has compared canal dimensions between reinforced and non-reinforced eyes; the durability claim rests on single-arm imaging after suture canaloplasty and on evidence that viscoelastic is transient [21,29,43,63]. Second, scaffold evidence is largely single-arm; HORIZON is the only large 5-year randomized trial and its comparator is cataract surgery alone, not canaloplasty [1,25,28], and real-world data do not consistently reproduce a scaffold advantage [65]. Third, scleral allograft reinforcement of Schlemm’s canal is unproven; published allograft outcomes address the uveoscleral cleft [12,34,53]. Fourth, the distal ceiling is fixed: roughly a quarter of outflow resistance lies beyond the canal and episcleral venous pressure sets a floor, so patients with elevated venous pressure (Sturge–Weber syndrome, thyroid eye disease, tight scleral buckles) should not be expected to respond [24,57].
Priority studies include a randomized comparison of reinforced versus non-reinforced canaloplasty with serial high-resolution anterior segment OCT morphometry as a co-primary endpoint; aqueous angiography to determine whether reinforcement recruits segmentally silent outflow territory; first-in-human feasibility work on intracanalicular biologic scaffolding; and, in any comparison of synthetic and biologic reinforcement, prespecified gonioscopic synechiae, inflammation and inlet-obstruction endpoints using common definitions, since synechia rates are not comparable across trials that define them differently [1,2,55].

5. Conclusions

Twenty years of canal surgery describe a coherent arc. Viscocanalostomy showed that Schlemm’s canal could be reopened without a bleb; tensioned canaloplasty showed that a permanent element outperforms viscoelastic and sustains lumen expansion for years; ab-interno catheterization made the restorative mechanism minimally invasive; and intracanalicular scaffolding showed in a 5-year randomized trial that holding the canal open reduces medication burden, slows field progression and lowers the need for incisional surgery. Acellular scleral allograft offers the prospect of the same durable reinforcement with a non-synthetic substrate native to the outflow region, a prospect that now requires direct testing inside the canal. Several questions remain unresolved: whether reinforcement, rather than dilation alone, accounts for durable canal patency; whether a biologic scaffold provokes less synechial and fibrotic reaction than synthetic hardware in the human angle; and whether allograft reinforcement can be delivered and retained within Schlemm’s canal. Randomized trials with serial anterior segment imaging and standardized gonioscopic endpoints are needed to answer them.

5.1. Method of Literature Search

A literature search of PubMed/MEDLINE was performed for English-language articles published from January 1950 through September 2026. The primary search combined the terms “canaloplasty,” “viscocanalostomy,” “Schlemm’s canal,” “Stegmann Canal Expander,” “Hydrus,” “gonioscopy-assisted transluminal trabeculotomy,” “scleral allograft,” and “bio-interventional” with “glaucoma,” “intraocular pressure,” or “outflow.” Supplementary searches addressed: (1) histopathologic and ultrastructural studies of explanted glaucoma implants, (2) reviews of conventional aqueous outflow physiology, including trabecular meshwork and episcleral venous pressure, and aqueous perfusion studies, (3) host responses to implanted biomaterials and biologic scaffolds, and (4) recent reviews and practice guidelines for open-angle glaucoma. Clinical trial reports, registry studies, review articles, meta-analyses, clinical practice guidelines, and laboratory study reports were eligible. Case reports were included only when they described device-related complications or unique intraoperative or histopathologic observations. Conference abstracts and non-peer-reviewed sources were excluded. Titles and then abstracts were screened, and articles were selected for final inclusion after full-text review.

5.2. Key References

Five references are highlighted as key references. Gedde (2026) [22] is the 2026 American Academy of Ophthalmology Preferred Practice Pattern, whose substantially expanded surgical section positions canal-based and non-penetrating procedures against filtration surgery. Mercieca (2025) [47] compared canaloplasty, deep sclerectomy, and viscocanalostomy in 600 eyes across nine units; the advantage of canaloplasty over viscocanalostomy widened as pressure targets tightened, which is the clinical signature expected of reinforcement. Radcliffe (2025) [52] is the largest real-world dataset of standalone canaloplasty combined with trabeculotomy and shows durable intraocular pressure reduction to 36 months in predominantly moderate and severe disease. Kerr (2026) [38] is a prospective international registry of trabecular meshwork-sparing catheter canaloplasty with a low reoperation rate. Tan (2026) [65] is a propensity-matched registry that found no advantage at 48 months for the Hydrus scaffold over the iStent inject bypass stent, an essential counterweight to the randomized trial data.

Author Contributions

A.L.: Formal analysis, Writing – review and editing. W.D.S.: Methodology, Formal analysis, Writing – review and editing. T.Y.T.T.: Formal analysis, Writing – review and editing. S.S.: Formal analysis, Writing – review and editing. L.W.H.: Formal analysis, Writing – review and editing. T.I.: Conceptualization, Methodology, Formal analysis, Writing – original draft, Writing – review and editing.:.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Disclosure

W.D.S. is a consultant for Iantrek. T.I. is the founder of, and holds equity in, Iantrek. The other authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.

References

  1. Ahmed IIK, De Francesco T, Rhee D, et al. Long-term outcomes from the HORIZON randomized trial for a Schlemm’s canal microstent in combination cataract and glaucoma surgery. Ophthalmology. 2022;129(7):742-51. [CrossRef]
  2. Ahmed IIK, Fea A, Au L, et al. A prospective randomized trial comparing Hydrus and iStent microinvasive glaucoma surgery implants for standalone treatment of open-angle glaucoma: the COMPARE study. Ophthalmology. 2020;127(1):52-61. [CrossRef]
  3. Allingham RR, de Kater AW, Ethier CR. Schlemm’s canal and primary open angle glaucoma: correlation between Schlemm’s canal dimensions and outflow facility. Exp Eye Res. 1996;62(1):101-9. [CrossRef]
  4. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol. 2008;20(2):86-100. [CrossRef]
  5. Badylak SF, Gilbert TW. Immune response to biologic scaffold materials. Semin Immunol. 2008;20(2):109-16. [CrossRef]
  6. Braunger BM, Fuchshofer R, Tamm ER. The aqueous humor outflow pathways in glaucoma: a unifying concept of disease mechanisms and causative treatment. Eur J Pharm Biopharm. 2015;95(Pt B):173-81. [CrossRef]
  7. Brown BN, Valentin JE, Stewart-Akers AM, et al. Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component. Biomaterials. 2009;30(8):1482-91. [CrossRef]
  8. Brusini P. Canaloplasty in open-angle glaucoma surgery: a four-year follow-up. ScientificWorldJournal. 2014;2014:469609. [CrossRef]
  9. Bull H, von Wolff K, Körber N, Tetz M. Three-year canaloplasty outcomes for the treatment of open-angle glaucoma: European study results. Graefes Arch Clin Exp Ophthalmol. 2011;249(10):1537-45. [CrossRef]
  10. Butt FR, Dhivagaran T, Stasso J, et al. Trabecular meshwork-based MIGS: efficacy, technique variability, and wound healing: a comprehensive review. J Clin Med. 2026;15(4):1490. [CrossRef]
  11. Byszewska A, Konopińska J, Kicińska AK, et al. Canaloplasty in the treatment of primary open-angle glaucoma: patient selection and perspectives. Clin Ophthalmol. 2019;13:2617-29. [CrossRef]
  12. Calvo E, De Francesco T, Vera L, et al. Bio-interventional uveoscleral outflow enhancement surgery for primary open-angle glaucoma: 2-year results of cyclodialysis with scleral allograft reinforcement. Ophthalmol Sci. 2025;5(4):100727. [CrossRef]
  13. Capitena Young CE, Ammar DA, Seibold LK, et al. Histopathologic examination of trabecular meshwork changes after trabecular bypass stent implantation. J Glaucoma. 2018;27(7):606-9. [CrossRef]
  14. Capitena Young CE, St Peter DM, Ertel MK, Pantcheva MB. Hydrus microstent malposition with uveitis-glaucoma-hyphema syndrome. Am J Ophthalmol Case Rep. 2022;25:101405. [CrossRef]
  15. Carreon T, van der Merwe E, Fellman RL, et al. Aqueous outflow: a continuum from trabecular meshwork to episcleral veins. Prog Retin Eye Res. 2017;57:108-33. [CrossRef]
  16. Chen RI, Purgert R, Eisengart J. Gonioscopy-assisted transluminal trabeculotomy and goniotomy, with or without concomitant cataract extraction, in steroid-induced and uveitic glaucoma: 24-month outcomes. J Glaucoma. 2023;32(6):501-10. [CrossRef]
  17. De Francesco T, Ianchulev T, Rhee DJ, et al. The evolving surgical paradigm of scleral allograft bio-tissue use in ophthalmic surgery: techniques and clinical indications for ab-externo and ab-interno scleral reinforcement. Clin Ophthalmol. 2024;18:1789-95. [CrossRef]
  18. Drüsedau MU, von Wolff K, Bull H, von Barsewisch B. Viscocanalostomy for primary open-angle glaucoma: the Gross Pankow experience. J Cataract Refract Surg. 2000;26(9):1367-73. [CrossRef]
  19. Eldaly MA, Bunce C, Elsheikha OZ, Wormald R. Non-penetrating filtration surgery versus trabeculectomy for open-angle glaucoma. Cochrane Database Syst Rev. 2014;2014(2):CD007059. [CrossRef]
  20. Ennerst CD, Fischinger IR, Tetz MR. Long-term outcome after canaloplasty and phacocanaloplasty in primary open angle glaucoma. J Glaucoma. 2024;33(11):867-73. [CrossRef]
  21. Fuest M, Kuerten D, Koch E, et al. Evaluation of early anatomical changes following canaloplasty with anterior segment spectral-domain optical coherence tomography and ultrasound biomicroscopy. Acta Ophthalmol. 2016;94(5):e287-92. [CrossRef]
  22. Gedde SJ, Bowden EC, Challa P, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern®. Ophthalmology. 2026;133(4):P1-103. [CrossRef]
  23. Goldberg DF, Orlich C, Flowers BE, et al. A randomized controlled trial comparing STREAMLINE canaloplasty to trabecular micro-bypass stent implantation in primary open-angle glaucoma. Clin Ophthalmol. 2024;18:2917-28. [CrossRef]
  24. Grant WM. Experimental aqueous perfusion in enucleated human eyes. Arch Ophthalmol. 1963;69:783-801. [CrossRef]
  25. Grieshaber MC, Grieshaber HR, Stegmann R. A new expander for Schlemm canal surgery in primary open-angle glaucoma: interim clinical results. J Glaucoma. 2016;25(8):657-62. [CrossRef]
  26. Grieshaber MC, Peckar C, Pienaar A, et al. Long-term results of up to 12 years of over 700 cases of viscocanalostomy for open-angle glaucoma. Acta Ophthalmol. 2015;93(4):362-7. [CrossRef]
  27. Grieshaber MC, Pienaar A, Olivier J, Stegmann R. Canaloplasty for primary open-angle glaucoma: long-term outcome. Br J Ophthalmol. 2010;94(11):1478-82. [CrossRef]
  28. Grieshaber MC, Schoetzau A, Grieshaber HR, Stegmann R. Canaloplasty with Stegmann Canal Expander for primary open-angle glaucoma: two-year clinical results. Acta Ophthalmol. 2017;95(5):503-8. [CrossRef]
  29. Grieshaber MC, Stegmann R, Grieshaber HR, Meyer P. Novel device for expanding Schlemm’s canal: a morphological study. Br J Ophthalmol. 2015;99(7):875-7. [CrossRef]
  30. Hamanaka T, Sakurai T, Fuse N, et al. Comparisons of Schlemm’s canal and trabecular meshwork morphologies between juvenile and primary open angle glaucoma. Exp Eye Res. 2021;210:108711. [CrossRef]
  31. Hong J, Xu J, Wei A, et al. Spectral-domain optical coherence tomographic assessment of Schlemm’s canal in Chinese subjects with primary open-angle glaucoma. Ophthalmology. 2013;120(4):709-15. [CrossRef]
  32. Huang H, Tian L, Sun X, Chen Y. En face optical coherence tomography detection of Schlemm’s canal in primary open angle glaucoma. Front Physiol. 2023;14:1214427. [CrossRef]
  33. Hübner L, Schlötzer-Schrehardt U, Weller JM, et al. Ultrastructural analysis of explanted CyPass microstents and correlation with clinical findings. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2663-73. [CrossRef]
  34. Ianchulev T, Weinreb RN, Calvo EA, et al. Bio-interventional cyclodialysis and allograft scleral reinforcement for uveoscleral outflow enhancement in open-angle glaucoma patients: one-year clinical outcomes. Clin Ophthalmol. 2024;18:3605-14. [CrossRef]
  35. Jabłońska J, Lewczuk K, Krix-Jachym K, et al. Five-year outcomes of first-generation iStent versus Hydrus microstent implantation combined with phacoemulsification in patients with open-angle glaucoma: a prospective non-randomized comparative study. J Clin Med. 2026;15(13):5076. [CrossRef]
  36. Jayaram H, Kolko M, Friedman DS, Gazzard G. Glaucoma: now and beyond. Lancet. 2023;402(10414):1788-801. [CrossRef]
  37. Johnstone MA. The aqueous outflow system as a mechanical pump: evidence from examination of tissue and aqueous movement in human and non-human primates. J Glaucoma. 2004;13(5):421-38. [CrossRef]
  38. Kerr N, Lubeck D, Barton K, et al. A prospective, real-world, multicenter study to support the role of ab-interno canaloplasty in glaucoma management. Am J Ophthalmol. 2026;284:235-46. [CrossRef]
  39. Kim J, Park DY, Bae H, et al. Impaired angiopoietin/Tie2 signaling compromises Schlemm’s canal integrity and induces glaucoma. J Clin Invest. 2017;127(10):3877-96. [CrossRef]
  40. Koerber N, Ondrejka S. 6-year efficacy and safety of iTrack ab-interno canaloplasty as a stand-alone procedure and combined with cataract surgery in primary open angle and pseudoexfoliative glaucoma. J Glaucoma. 2024;33(3):176-82. [CrossRef]
  41. Koerber NJ. Canaloplasty in one eye compared with viscocanalostomy in the contralateral eye in patients with bilateral open-angle glaucoma. J Glaucoma. 2012;21(2):129-34. [CrossRef]
  42. Konopińska J, Gołaszewska K, Saeed E. Long-term efficacy and safety of ab-externo canaloplasty in the Polish Caucasian population with open-angle glaucoma: a 3-year retrospective study. PLoS One. 2024;19(10):e0312236. [CrossRef]
  43. Kuerten D, Plange N, Becker J, et al. Evaluation of long-term anatomic changes following canaloplasty with anterior segment spectral-domain optical coherence tomography and ultrasound biomicroscopy. J Glaucoma. 2018;27(1):87-93. [CrossRef]
  44. Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: circumferential viscodilation and tensioning of Schlemm’s canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults: interim clinical study analysis. J Cataract Refract Surg. 2007;33(7):1217-26. [CrossRef]
  45. Lewis RA, von Wolff K, Tetz M, et al. Canaloplasty: three-year results of circumferential viscodilation and tensioning of Schlemm canal using a microcatheter to treat open-angle glaucoma. J Cataract Refract Surg. 2011;37(4):682-90. [CrossRef]
  46. Li W, Geng Y, Shi K, et al. Efficacy and safety of goniotomy and gonioscopy-assisted transluminal trabeculotomy for exfoliation glaucoma: a systematic review and single-arm meta-analysis. Front Med (Lausanne). 2026;13:1718315. [CrossRef]
  47. Mercieca K, Azzopardi M, Vallabh NA, et al. Comparison of outcomes of deep sclerectomy, canaloplasty, and viscocanaloplasty: a multicenter study. J Glaucoma. 2025;34(5):349-57. [CrossRef]
  48. Montesano G, Ometto G, Ahmed IIK, et al. Five-year visual field outcomes of the HORIZON trial. Am J Ophthalmol. 2023;251:143-55. [CrossRef]
  49. Ondrejka S, Körber N, Dhamdhere K. Long-term effect of canaloplasty on intraocular pressure and use of intraocular pressure-lowering medications in patients with open-angle glaucoma. J Cataract Refract Surg. 2022;48(12):1388-93. [CrossRef]
  50. Otarola F, Virgili G, Shah A, et al. Ab-interno trabecular bypass surgery with Schlemm’s canal microstent (Hydrus) for open angle glaucoma. Cochrane Database Syst Rev. 2020;3(3):CD012740. [CrossRef]
  51. Overby DR, Zhou EH, Vargas-Pinto R, et al. Altered mechanobiology of Schlemm’s canal endothelial cells in glaucoma. Proc Natl Acad Sci U S A. 2014;111(38):13876-81. [CrossRef]
  52. Radcliffe NM, Harris J, Garcia K, et al. Standalone canaloplasty and trabeculotomy using the OMNI surgical system in eyes with primary open-angle glaucoma: a 36-month analysis from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight). Am J Ophthalmol. 2025;271:436-44. [CrossRef]
  53. Reiss G, Francis B, Nguyen Q, et al. Standalone bio-interventional uveoscleral outflow enhancement for intraocular pressure reduction in open-angle glaucoma: one-year results from a prospective multicenter real-world evidence study (NCT05506423). PLoS One. 2026;21(6):e0351552. [CrossRef]
  54. Richter GM, Takusagawa HL, Sit AJ, et al. Trabecular procedures combined with cataract surgery for open-angle glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2024;131(3):370-82. [CrossRef]
  55. Samuelson TW, Chang DF, Marquis R, et al. A Schlemm canal microstent for intraocular pressure reduction in primary open-angle glaucoma and cataract: the HORIZON study. Ophthalmology. 2019;126(1):29-37. [CrossRef]
  56. Shaarawy T, Nguyen C, Schnyder C, Mermoud A. Five year results of viscocanalostomy. Br J Ophthalmol. 2003;87(4):441-5. [CrossRef]
  57. Sit AJ, McLaren JW. Measurement of episcleral venous pressure. Exp Eye Res. 2011;93(3):291-8. [CrossRef]
  58. Smit BA, Johnstone MA. Effects of viscoelastic injection into Schlemm’s canal in primate and human eyes: potential relevance to viscocanalostomy. Ophthalmology. 2002;109(4):786-92. [CrossRef]
  59. Stamer WD, Acott TS. Current understanding of conventional outflow dysfunction in glaucoma. Curr Opin Ophthalmol. 2012;23(2):135-43. [CrossRef]
  60. Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients. J Cataract Refract Surg. 1999;25(3):316-22. [CrossRef]
  61. Sunaric-Mégevand G, Leuenberger PM. Results of viscocanalostomy for primary open-angle glaucoma. Am J Ophthalmol. 2001;132(2):221-8. [CrossRef]
  62. Szurman P. Advances in canaloplasty: modified techniques yield strong pressure reduction with low risk profile. J Clin Med. 2023;12(8):3031. [CrossRef]
  63. Takahashi H, Tanito M, Yokoyama M, et al. Two cases of intraoperative anterior chamber angle observation using ophthalmic endoscope in viscocanalostomy. Am J Ophthalmol. 2004;138(6):1060-3. [CrossRef]
  64. Tamm ER, Braunger BM, Fuchshofer R. Intraocular pressure and the mechanisms involved in resistance of the aqueous humor flow in the trabecular meshwork outflow pathways. Prog Mol Biol Transl Sci. 2015;134:301-14. [CrossRef]
  65. Tan JCK, Clement C, Healey P, et al. Long-term comparative outcomes of Hydrus versus iStent inject microinvasive glaucoma surgery implants combined with cataract surgery. Br J Ophthalmol. 2026;110(1):52-8. [CrossRef]
  66. Tan NE, Young CEC, Seibold LK. Canaloplasty and trabecular bypass glaucoma surgery: indications and outcomes. Curr Opin Ophthalmol. 2026;37(3):259-64. [CrossRef]
  67. Tsutsui A, Hamanaka T, Manabe K, et al. Histologic findings of trabecular meshwork and Schlemm’s canal after microhook ab-interno trabeculotomy. J Glaucoma. 2021;30(2):203-5. [CrossRef]
  68. Vemulapalli K, Gandhewar R, Yim TW, et al. Minimally invasive trabecular meshwork surgery for open-angle glaucoma. Cochrane Database Syst Rev. 2026;7(7):CD015186. [CrossRef]
  69. Yan X, Li M, Chen Z, et al. Schlemm’s canal and trabecular meshwork in eyes with primary open angle glaucoma: a comparative study using high-frequency ultrasound biomicroscopy. PLoS One. 2016;11(1):e0145824. [CrossRef]
  70. Zhu D, Shah P, Zhang C, et al. Standalone canaloplasty and trabeculotomy using the OMNI surgical system in patients with open angle glaucoma: a systematic review and meta-analysis. J Glaucoma. 2025;34(11):949-58. [CrossRef]
Table 1. Five Generations of Schlemm’s Canal Surgery.
Table 1. Five Generations of Schlemm’s Canal Surgery.
Generation,
Era
Technique Reinforcement Approach Trabecular Meshwork Status Key Durability Signal
First,
1999–present
Viscocanalostomy None (transient viscoelastic) Ab-externo Preserved IOP 15.4 mmHg at 5 years and 15.5 at 10 years; viscoelastic absent by day 1 [26,63]
Second,
2005–present
Suture-tensioned canaloplasty Permanent 10-0 polypropylene under tension Ab-externo Preserved, re-tensioned Canal height +351% at 20 months; efficacy to 10–11 years [20,43]
Third,
2013–present
Ab-interno canaloplasty (iTrack, OMNI, STREAMLINE) None (transient viscoelastic) Ab-interno Preserved (incised with OMNI trabeculotomy) IOP reduction to 36–42 months; small series to 6 years [40,49,52]
Fourth,
2012–present
Intracanalicular scaffold (Hydrus, Stegmann Canal Expander) Permanent synthetic Ab-interno (Hydrus)
Ab-externo (Expander)
Bypassed at inlet; distended 5-year randomized trial; canal held open over 9 mm; cumulative peripheral anterior synechiae 14.6% vs 3.7% at 5 years [1,29]
Fifth,
2022–present
Allograft-reinforced cyclodialysis Permanent biologic (acellular sclera) Ab-interno Untouched; target is the uveoscleral pathway 24-month data; no migration, rejection or persistent inflammation; peripheral anterior synechiae not yet reported [12,53]
IOP, intraocular pressure. Note: Fifth-generation data derive from the uveoscleral compartment; intracanalicular biologic reinforcement is investigational.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.